Case Report

Radiopharmaceuticals and the Ophthalmologist

Sunny Chi Lik Au

Department of Ophthalmology, Tung Wah Eastern Hospital, Hong Kong

Corresponding Author: Sunny Chi Lik Au, MRCSEd (Ophth), AFCOphthHK, Department of Ophthalmology, Tung Wah Eastern Hospital, Hong Kong, Tel: (852) 2162 6909; E-mail: kilihcua@gmail.com

Received: 19 July 2020; Accepted: 29 July 2020; Published: 31 July 2020

Introduction
Radiopharmaceuticals are not commonly used in ophthalmologist hands, but occasionally used for head and neck cancers [1], especially over the southeastern Asia [2]. With close proximity between the eyes and the sinuses, ophthalmologists sometimes encounter these oncological patients with ocular complaints secondary to orbital invasion of tumor [3]. Here, we outline an ophthalmologist encounter with clinical radiation hazard from such, and patient’s problem with after-life cremation.

Case Report
A 73-year-old male cancer patient was admitted to hospital with right eye progressive swelling, redness, and blurring of vision. He was running a fever of 38°C, and was in septic shock with fluid resuscitation. Being drowsy with poor response, he failed to cooperate the extraocular movement examination and visual acuity test. Bedside physical examinations found erythematous swelling over the right periocular skin, right eyelids swelling with conjunctival injection, and mild right eye chemosis. Anterior chamber was quiet on portable slit lamp examination, and mydriatic drops were given preparing for fundus examination. Left eye appeared normal. Intraocular pressure was 20 and 15mmHg over right and left eye respectively. The provisional diagnosis was systemic sepsis from right orbital cellulitis.

Head computed tomography scan were done upon waiting for pupil dilatation, (Figure 1) but films revealed no evidence of subperiosteal abscess. In contrast, some metallic seeds with streak artifacts over right nasal cavity were seen. (Figure 2) Patient deteriorated shortly after the scan, and his advance
healthcare directive of “do-not-attempt cardiopulmonary resuscitation” was respected. Three radiopaque radioactive seeds (arrowed) were seen with the bottom one embedded in the dislodged tumor mass down the maxillary sinus. Note patient’s history of right maxillectomy was also evidenced.

**Figure 1:** Computed tomography scan of the head in coronal cut.

**Figure 2:** Computed tomography scan of the head in transverse cut
Two radiopaque radioactive seeds (arrowed) were seen at the level of ethmoid sinus. Right medial rectus muscle was displaced temporally by the bulky tumor mass.

Interviewed with his relatives, patient had left nasal cavity plasmacytoma history, with Cobalt-60 radiotherapy of 69.5Gy/65Fr in 1982; and right maxillary sinus sarcomatoid carcinoma with maxillectomy in 2015. Right facial recurrence in May 2017 was managed by surgical excision, yet lung metastasis was found in May 2018. Six cycles of docetaxel plus cyclophosphamide were given, followed by imatinib according to next-generation sequencing results.

In addition, they also volunteered the striking history of oncological implants two weeks ago in another city. Judging from their description, iodine-125 radioactive seeds implantation was suspected. Radioactivity measured around the face of the dead body at 50cm was 3.5 uSv/hr. Luckily, none of the attending physicians were pregnant. However, all did not wear any protective shield upon handling of the patients. For radiation safety sake, cremation was not allowed, and burial for at least 2 years was required by local law. Disappointed by non-adherence to patient’s cremation wish, deceased relatives expressed difficulties on finding a single burial place under the deadly coronavirus disease 2019 strike in the city.

**Discussion**

Radioactive implants were sometimes used as radiopharmaceuticals [4], such as gold-198 [5], iodine-125 [6,7,8], iodine-131 [9], radium-223 [10], and yttrium-90 [11] for prostate [10], lung [7], head and neck [8,9], thyroid [9], cervix cancer [12], choroidal melanoma [13], or hepatocellular carcinoma [11] etc. They come in different radiation dosage with variable half-lives [14], thus different implantation-to-cremation periods (Table 1).

<table>
<thead>
<tr>
<th>Radiopharmaceutical</th>
<th>Usual dosage range (GBq)</th>
<th>Half life (days)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gold-198</td>
<td>12</td>
<td>2.7</td>
</tr>
<tr>
<td>Iodine-125</td>
<td>23</td>
<td>60</td>
</tr>
<tr>
<td>Iodine-131</td>
<td>35.5</td>
<td>8</td>
</tr>
<tr>
<td>Radium-223</td>
<td>3.5</td>
<td>11.4</td>
</tr>
<tr>
<td>Yttrium-90</td>
<td>1-2</td>
<td>2.7</td>
</tr>
</tbody>
</table>

Other than lifetime caring issues, doctors cares patients’ after-death wishes. Cremation, burial, donation, and mummification are some of the ways for body disposition. Although radioactive implant is usually given to those with reasonable life expectancy, sudden death on these oncological patients is not predictable. Patient should seriously be briefed twice on their after-death arrangement before the implantation.
Conclusion
Patients with radiopharmaceuticals carries potential risk of radiation hazard towards their carers in life, or even towards cremation workers after their death. This article aims to update ophthalmologists on the properties of different radiopharmaceuticals.

Declaration of Interest
There is no conflict of interest to disclose

Funding
There is no funding support for this manuscript

References


Clinical Question Quiz:

Oncological patient with implantation of which of the following radioactive nuclides (with usual dosage range) five months before death is unsafe to undergo cremation with acceptable radioactivity level?

[A] Gold-198
[B] Iodine-125
[C] Radium-223
[D] Yttrium-90

Answer: [B] Iodine-125

The 60-days half-life of Iodine-125 takes around 24 months to complete 12 half-lives for a usual dosage range of 2-3GBq to reach the safety level of 1 MBq for cremation.